Perioperative Treatment of Hepatoid Adenocarcinoma of Stomach
Recruiting
Phase 2
Interventional Study
Hepatoid Adenocarcinoma of Stomach
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 18 – 75
- Sex
- Any
- Trial phase
- Phase 2
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 30 (estimated)
- Sponsor
- Peking University Cancer Hospital & Institute · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The goal of this clinical trial is to learn if treatment modality including Disitamab Vedotin （RC48）, Oxaliplatin，Tegafur,Gimeracil and Oteracil Porassium Capsules （SOX）and Sindillimab works to treat locally advanced hepatoid adenocarcinoma of stomach. It will also learn about the safety of this modality. The main aim it aims to achieve are:
* To evaluate the perioperative efficacy of RC48 combin…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* The histological type of gastric hepatoid adenocarcinoma was confirmed by pathological biopsy；
* HER2 expression (Immunohistochemistry: 1+,2+,3+);
* Patients with clinical stage II-III;
* Those who are expected to complete R0 excision;
* ECOG score 0\~1;
* Generally in good co…
Contacts